

1 Viral kinetic modeling and clinical trial simulation 2 predicts disruption of respiratory disease trials by 3 non-pharmaceutical COVID-19 interventions

4 Simon Arsène^{1, *}, Claire Couty^{1, *}, Igor Faddeenkov^{1, *}, Natacha Go^{1, *}, Solène
5 Granjeon-Noriot^{1, *}, Daniel Smít¹, Riad Kahoul¹, Ben Illigens^{1, 3}, Jean-Pierre Boissel¹,
6 Aude Chevalier², Lorenz Lehr², Christian Pasquali², and Alexander Kulesza^{1, †}

7 ¹Novadiscovery SA, Lyon, France

8 ²OM Pharma, Meyrin, Switzerland

9 ³Dresden International University, Dresden, Germany

10 †corresponding author(s): Alexander Kulesza (Alexander.Kulesza@novadiscovery.com)

11 *these authors contributed equally to this work

12 ABSTRACT

Clinical research in infectious respiratory diseases has been profoundly affected by non-pharmaceutical interventions (NPIs) against COVID-19. On top of trial delays or even discontinuation which have been observed in all disease areas, NPIs altered transmission pattern of many seasonal respiratory viruses which followed regular patterns for decades before the pandemic. Clinical trial design based on pre-pandemic historical data therefore needs to be put in question. In this article, we show how knowledge-based mathematical modeling can be used to address this issue. We set up an epidemiological model of respiratory tract infection (RTI) sensitive to a time dependent between-host transmission rate and coupled this model to a mechanistic description of viral RTI episodes in an individual patient. By reducing the transmission rate when the lockdown was introduced in the United Kingdom in March 2020, we were able to reproduce the perturbed 2020 RTI disease burden data. Using this setup, we simulated several NPIs scenarios of various strength (none, mild, medium, strong) and conducted placebo-controlled *in silico* clinical trials in pediatric patients with recurrent RTIs (RRTI) quantifying annual RTI rate distributions. In interventional arms, virtual patients aged 1-5 years received the bacterial lysate OM-85 (approved in several countries for the prevention of pediatric RRTIs) through a pro-type I immunomodulation mechanism of action described by a physiologically based pharmacokinetics and pharmacodynamics approach (PBPK/PD). Our predictions showed that sample size estimates based on the ratio of RTI rates (or the post-hoc power of fixed sample size trials) are not majorly impacted under NPIs which are less severe (none, mild and medium NPIs) than a strict lockdown (strong NPI). However, NPIs show a stronger impact on metrics more relevant for assessing the clinical relevance of the effect such as absolute benefit. This dichotomy shows the risk that successful trials (even with their primary endpoints being met) still get challenged in risk benefit assessment during the review of market authorization. Furthermore, we found that a mild NPI scenario already affected the time to recruit significantly when sticking to eligibility criteria complying with historical data. In summary, our model predictions can help rationalize and forecast post-COVID-19 trial feasibility. They advocate for gauging absolute and relative benefit metrics as well as clinical relevance for assessing efficacy hypotheses in trial design and they question eligibility criteria misaligned with the actual disease burden.

14 Introduction

15 The COVID-19 pandemic and consecutive response measures to contain the spread of SARS-CoV-2 in the form of non-
16 pharmaceutical interventions (NPIs) have not only changed people's life and health¹ but also the process of developing vaccines
17 and potential treatments². This has led to a rapid pursue of different immunization strategies against the virus^{3,4}, a surge of
18 drug repurposing and the screening of new treatment candidates^{5,6}.

19 Clinical development in non-COVID-19 disease areas, however, has been substantially impaired⁷. Due to the high number
20 of COVID-19 cases during the pandemic in 2020, trial initiation dropped by up to 30 % in the USA⁸. During the first wave
21 of the pandemic, more than 1000 trials were stopped as a consequence⁹. Social distancing and quarantine measures have
22 negatively affected patients participation in clinical trials. The surge in hospitalizations of COVID-19 patients also affected
23 personnel's capacity to conduct trials¹⁰ and has led to incomplete or delayed data collection in ongoing trials with foreseeable
24 difficulties for patient enrolment and follow-up in upcoming trials. Trialists expect that the collateral impact of COVID-19 on
25 clinical trials will be persist for several years¹¹, given that intermittent containment measures are possible beyond the year

26 2025¹².

27 This is especially critical for trials investigating diseases of the pulmonary system. About 10% of all trials conducted in
28 Europe in pre-COVID-19 times were on respiratory diseases^{13,14}. Due to COVID-19 containment measures that intend to
29 attenuate SARS-CoV-2 transmission, respiratory disease transmission is altered at the population scale, and/or there might be
30 under-reporting of respiratory diseases to healthcare services (see a recent systematic review by Alqahtani *et al.* (2021)¹⁵).
31 Recent reports show that seasonal dynamics of common respiratory tract infections (RTIs) have almost vanished during the
32 COVID-19 pandemic^{16–19}. In England, overall fewer cases of common cold, flu, and bronchitis have been reported during the
33 lockdown²⁰. Hospitalization for acute bronchiolitis in children less than 1 year old saw a significant reduction, on the order of
34 70 – 90% comparing 2020 with earlier years²¹. For COPD (often triggered by viral infections), healthcare professionals in
35 Europe have reported fewer cases in community and acute hospital settings^{22,23} and a decline in asthma exacerbations has
36 been reported as well²⁴. While this decline may be regarded as a positive side-effect of the pandemic, it is only temporary
37 and rebounding of the respiratory disease burden can happen^{25,26}. At the same time, respiratory disease prophylaxis and
38 international trials are strongly affected by these drastic changes because the design of clinical trials is usually conceived
39 from pre-pandemic settings, e.g. the sample size calculation and the choice of endpoints and eligibility are based on historical
40 interventional and observational. Therefore, clinical trial feasibility in respiratory diseases remains an open question in the
41 medium term.

42 Modeling and simulation might be an approach to address the lack in representativity of historical data if forecasts of
43 disease transmission can be joined with clinical trial simulation. For example, simulated clinical trials have provided the
44 means to test a multitude of design choices^{27–30} and became a field gaining attraction throughout regulatory agencies³¹. The
45 COVID-19 pandemic has already transformed the modeling and simulation community. For example, governments rely on
46 mathematical – often epidemiological – between-host viral transmission models to predict the evolution of the pandemic and
47 to take evidence-based decisions³². On the other hand, viral kinetic modeling, focusing on the patient immunology and viral
48 infection resolution, can be used to accelerate drug development³³.

49 However, to our knowledge, there is currently no available modeling approach that can simulate RTI prophylaxis trials
50 under COVID-19 pandemic conditions and that could serve to better inform respiratory disease trials. Based on the applicability
51 of viral kinetic models on the population and individual scale (i.e., immunology) for a broad variety of viruses, we hypothesized
52 that a knowledge-based mechanistic model as schematized in Figure 1 could be used for *in silico* RTI prophylaxis trial
53 simulation and to forecast trial feasibility. After matching known viral disease burden seasonality, intra- and inter-patient
54 variability in RTI resolution and efficacy data, we built a mechanistic model and simulated placebo-controlled *in silico* trials
55 in 1-5 year old pediatric patients with recurrent RTIs (RRTI) treated with the immunomodulator OM-85 (an agent approved
56 in several countries for RTI prophylaxis in this population used here as a case study) under 4 different hypotheses of NPI
57 intensities and assessed efficacy and benefit metrics as a function of NPI intensity. Subsequently, we explored sample size and
58 recruitment considerations as aspects of trial feasibility.

59 Results

60 Effect of NPIs on RTI disease burden

61 Our epidemiological model is based on a compartmental approach describing susceptible, infected, recovered and again
62 susceptible (SIRS) individuals and explicitly describes transmission, recovery, and immunity loss rates (Figure 2a, Methods).
63 As representative comparator, we used the 5-year average and the 2019-2020 upper and lower RTI (URTI and LRTI) incidence
64 from the communicable and respiratory disease report 2019 to 2020 published in the UK by the Royal College of General
65 Practitioners (RCGP)³⁴ (points and full lines in Figure 2b). To model NPI, starting at week 12 in 2020, we decreased the
66 scaling factor of the viral transmission rate (b_0 , Supplementary Methods: Between-host SIRS model) by 17.5% to reproduce
67 the difference between the unperturbed 5-year average and the perturbed 2019-2020 URTI and LRTI incidence with lockdown.
68 Results of the simulations are displayed as dashed lines in Figure 2b. Simulations and data show a similar strong decline of
69 the disease incidence with the beginning of the lockdown in the UK during March 2020 (week 10-14)³⁵ while the 2019-2020
70 disease burden closely follows the 5-year average (as reported in Lacobucci *et al.* (2020)²⁰). With the adjusted transmission
71 rate and otherwise unchanged parameters, the root mean square deviation (RMSD) for the weekly incidence per 100,000 of the
72 simulation *vs.* data are 82 and 96 (unperturbed simulation *vs.* 5-year average data and perturbed simulation *vs.* 2019-2020,
73 data, respectively), which is smaller than the variability within the observed data before lockdown (RMSD of 102 for the 5-year
74 average *vs.* 2019-2020 data for the time points considered). Furthermore, reproduction of RTI incidence broken down into
75 URTIs and LRTIs (Supplementary Figure S1) shows convincing capability to describe the effect of transmission perturbation
76 on RTIs. Supported by this agreement, we applied this epidemiological model to modulate the instantaneous probability of
77 exposure to RTI-causing viruses in our *in silico* trials with four different NPI scenarios.

78 **Effect of NPIs on efficacy of RTI prophylaxis**

79 To represent the effect of different NPI scenarios for a 2-year clinical trial (when NPIs is introduced at the end of month 12, as
80 an illustrative example), we defined scenarios where the transmission rate is decreased by 5%, 15% and 25% (Figure 3a). We
81 quantified the effect of NPIs on the efficacy of RTI prophylaxis by running *in silico* clinical trials using our mechanistic model
82 applied to the oral immunomodulator OM-85 in a pediatric population suffering from recurrent RTIs. For assessing the efficacy
83 of a prophylactic treatment absolute and relative metrics have been suggested^{36,37} and therefore we report model predictions
84 for these metrics (Figure 3, Methods): absolute benefit (AB, difference between rate of RTI in both groups, Figure 3b), event
85 rate ratio (ERR, ratio of RTI rates between both groups, Figure 3c), and two-dimensional analysis of rates of RTIs in treated vs.
86 untreated patients (Effect Model, Methods: Efficacy analysis, Figure 3d). We define here the RTI rate as the number of RTIs
87 counted during the 12-month follow-up period (year 2 of the trial).

88 The absolute benefit of OM-85 decreases in parallel to the reduction of the transmission rate which leads to a decrease in
89 the number of preventable episodes: no reduction of the transmission rate: 1.53-2.74, 5% reduction: 1.16-1.98, 15% reduction:
90 0.60-1.14 and 25% reduction: 0.08-0.46 prevented RTI episodes. Assuming that an AB of 1 prevented RTI episode per year
91 would be clinically relevant in a given context (see Discussion), only NPI-induced transmission rate reduction < 15% fulfills
92 this criterion.

93 The ERR quantifies efficacy based on event rates in the treated group relative to the control group. It is a common metric
94 for performing statistical hypothesis testing with negative binomially distributed count data and may also be used for sample
95 size estimations. We find that the ERR does not vary considerably in all but the strongest NPI scenario (no reduction of the
96 transmission rate: 0.50-0.69, 5% reduction: 0.53-0.70, 15% reduction: 0.51-0.73 and 25% reduction: 0.50-0.87, Figure 3c). In
97 consequence, all analyses based on the ERR (i.e., sample size estimations or post-hoc power analyses) are expected to be only
98 affected under strong NPI (e.g. strict lockdown).

99 To harmonize the interpretation of the different efficacy metrics (see e.g., Tripepi *et al.*³⁶), we compared the RTI rates in the
100 treated group (R_t) vs. RTI rates in the control group (R_c) directly in a two-dimensional analysis (Effect Model, 3d). Because
101 R_c is often used to define the risk for RTI, this analysis characterizes the efficacy as a function of the risk. In all scenarios
102 with nonzero NPI-induced viral transmission rate reduction in year 2, virtual patients experienced fewer RTIs than in year 1
103 (≥ 5 ; required by eligibility criterion, no lockdown in year 1). A transmission rate reduction by 5% showed a reduction of 1.1
104 RTIs on average (control group RTI rates are 4.0 vs 5.1 with 5% reduction, $p < .001$, two-tailed Students t-test). Transmission
105 rate reduction by 15% and 25% showed reduction of RTI rates of 2.8 and 4.3 RTIs with respect to the non-perturbed scenario
106 (control group RTI rate are 2.3 and 0.8 vs. 5.1 with 0% reduction, both p values are $< .001$).

107 We then re-analyzed the efficacy distributions after the 12-month follow-up during the perturbed year 2 in relation to
108 thresholds or for assumed clinical relevance (AB and R_c) and statistical significance of the trial (ERR) directly in the x-y plane
109 of Figure 3d. We indicate a region matching three conditions (orange area in Figure 3d, lower right quadrant): i) recurrent RTI
110 with more than 3 RTIs per year (in real-life clinical trials recurrent RTI is often defined as 3 or more RTIs in the previous year
111 and clinical benefit is considered to prevent recurrence of RTI) as well as ii) an absolute benefit of at least 1 RTI per year under
112 which significant clinical benefit becomes less evident to demonstrate and iii) a rate reduction of 20% in RTI rate which is a
113 typical hypothesis for confirmatory trial design efficacy (that can be demonstrated with reasonable sample size and be clinically
114 relevant). The percentage of *in silico* clinical trials complying with all three criteria is 92.8 %, 0.0 % and 0.0 % for the mild,
115 medium, and strong NPI scenarios, respectively compared to 98.2 % when no NPI is applied. We thus regard trials conducted
116 as feasible when viral transmission rates are reduced by 5% but not more than 15%, even though they may still meet their
117 endpoints (given that patient selection is not impaired in our simulation scenario, see Figure 3a).

118 **Effect of NPI scenario on recruitment**

119 We gauged recruitment issues for RTI prophylaxis trials with estimations of the sample size estimated for a hypothesized efficacy
120 in a given at-risk population (as a function of NPI strength) and needed power along with a more practical time-to-recruit
121 consideration for given eligibility criteria (Figure 3e-f).

122 The sample size estimations commonly used in RTI prophylaxis trial designs are based on ERR assuming that RTI count
123 data are negative binomially distributed. We have therefore used a sample size estimation algorithm (Methods) using the ERR
124 (and negative binomial dispersion coefficient) obtained from R_c and R_t distributions in our *in silico* trials for a significance level
125 of $\alpha = 0.025$. Our sample size estimations as a function of NPI strength closely follow the trend of the ERR itself (no reduction
126 of the transmission rate: 40-79, 5% reduction: 42-71, 15% reduction: 55-89 and 25% reduction: 129-417, Figure 3e). Except
127 for strong NPI, those estimates are in line with the unperturbed scenario (NPI do not affect patient selection in this example).

128 We estimated the time required to recruit the estimated sample sizes (Figure 3e) if NPIs were started at the beginning of year
129 1 (selection year) and by assuming a constant hypothetical screening rate of 1000 patients per year. A slight reduction of the
130 transmission rate – as small as 5 % – increases the time to recruit by about 50 % from 0.23-0.45 years to 0.41-0.69 years). The
131 medium and strongest NPI scenarios (15% and 25% transmission rate reduction, respectively) lead to infeasible recruitment

132 times (3-4 years and 169-546 years respectively).

133 Discussion

134 SIRS models are compartmental models which can describe infection prevalence dynamics on the population level without
135 explicitly modeling each individual. They can be also used to reproduce periodic seasonality or attenuation of an epidemic,
136 for example using time-dependent parametrization. Nonpharmaceutical interventions (NPIs) to help control the COVID-19
137 pandemic such as lockdown measures or obligations to wear masks have been imposed by policy makers. More generally,
138 behavioral changes such as improved hygiene (e.g. washing hands more frequently), avoiding closed rooms and social distancing
139 have been adopted in society. NPIs are assumed to be able to decrease the transmission of the virus between the infected and
140 susceptible parts of the population. Applying this mechanistic rationale to the SIRS model, different NPI strengths can then be
141 systematically mapped to different transmission-related parameters. The SIRS model's outcome represents therefore the average
142 instantaneous probability density to contract a RTI in the described population under different NPI strength hypotheses. For
143 assessing the capabilities to reproduce realistic RTI disease burden under NPI, we ran our epidemiological SIRS model (Figure
144 2a) with and without scaling of the viral transmission rate to replicate the (2014-2019) average 5-year URTI and LRTI disease
145 burden in the UK versus the 2019-2020 data which captured the effect of the first lockdown through (Figure 2b). Notice that the
146 vast majority of RTI are considered to be of viral origin³⁸). We calibrated the SIRS model with heterogeneous viral prevalence
147 data in a knowledge driven manner, which limits the degrees of freedom to calibrate the model to the data. Nevertheless, we
148 achieved an acceptable agreement (RMSD prediction-data smaller than the 5-year average vs. 2019-2020 RMSD of 102 per
149 100,000 in our reference data). This agreement convinced us to use the simulated instantaneous RTI prevalence as modulator
150 for the time-dependent instantaneous probability of an individuals exposure to viruses, where each exposure is evaluated by the
151 within-host immunological model of RTI in an individual patient. While the use of retrospective epidemiological data about
152 incidence rates in the time period of interest may be directly used for the coupling to the within-host model, explicit simulation
153 allows to plausibly adjust and extrapolate this information (e.g. to another NPI scenario). As a limitation of the chosen approach,
154 feedback from the patient scale back to the population scale (e.g. how immunomodulation can reduce viral shedding and thus
155 transmission) is more challenging to implement. Additionally, no data are available to calibrate the OM-85 effect on viral
156 shedding or the efficacy under lockdown. Therefore, we needed to assume that both treatment effect and transmission are
157 independent factors.

158 The central aspect of this work is to determine, rationalize and interpret the possible changes induced by lockdown and
159 other NPIs for pandemic containment on respiratory disease trials with emphasis on RTI prophylaxis. A clinical trial has
160 two general objectives: first, to demonstrate non-zero efficacy of the interventional strategy, a binary question with a binary
161 answer given by a statistical test; second, to estimate the size of the clinical benefit for benefit-risk assessment. Well-designed
162 trials fulfil both objectives through characterizing the efficacy with a quantitative measure. Not always, however, are common
163 efficacy measures equally suitable for statistical testing and estimation of the clinical effect size. In recurrent RTIs, the event
164 rates ratio (ERR) is often used for statistical hypothesis testing as this measure applies to negative binomially distributed count
165 data^{39,40}. Nevertheless, a measured treatment efficacy that is relative to the control group event rate, is at-risk of incompletely
166 representing the clinical benefit, in case of low event rate - as in times of NPIs to mitigate the COVID-19 pandemic. We
167 therefore ran *in silico* clinical trials (based on the SIRS model, the within-host immunological model of RTI in an individual
168 patient, virtual population and a simulation protocol resembling pediatric OM-85 trials) reproducing existing clinical efficacy
169 data of OM-85 in a pediatric population suffering from recurrent RTI. To balance the interpretation for statistical significance
170 versus clinical benefit considerations of these *in silico* trials we applied different efficacy metrics (AB and ERR) and reconciled
171 them in a two-dimensional analysis of treated vs. untreated rates (termed Effect Model, see Methods).

172 Sample size estimation is of crucial importance for planning clinical trials. For this, hypotheses on expected efficacy and
173 chosen statistical power to detect it are needed and these may have to be adapted to the current pandemic context. Second, it is
174 important to consider how much the efficacy in a trial can differ from an efficacy hypothesis used for the planning, especially
175 when perturbations arise after the trial has been planned or when sample size estimates based on historical data need to be
176 used. Here, the post-hoc power obtained from the statistical analysis of the trial outcome might be perturbed under NPI. The
177 analysis of the NPI-dependent efficacy of OM-85 for RTI prophylaxis revealed that the ERR remains unchanged over a broad
178 range of NPI scenarios. Because ERR is used for statistical testing and sample size calculations, both the estimated sample size
179 and the post-hoc power, are not substantially affected unless strong NPIs, such as strict lockdown, are applied. In such case,
180 however, the post-hoc power of trials may be reduced for a given sample size and consequently trialists should consider an
181 adapted efficacy scenario for obtaining more realistic estimates.

182 The situation is different for metrics of the clinical benefit which assess the benefit-risk ratio. Depending on the exact
183 context and affected population, the definition of clinical relevance may vary. For example, prophylaxis of few LRTI episodes
184 in neonates (often associated with inception of asthma) will be clinically relevant compared to prophylaxis of a much higher
185 number of URTIs needed for clinical relevance in pre-school children, reflecting the different effect on patients lives and/or

186 long-term consequences. First, children frequently suffer from RTIs (especially URTIs) and 3 RTI episodes per year can be
187 considered a normal physiological behavior⁴¹. Thus, prevention of recurrence (>3) of RTIs (of which most are URTIs) appears
188 to be clinically relevant, however, our analysis has shown that under medium and strong NPI, the annual control group RTI rate
189 is already smaller than 3, even though it was fulfilling the definition of recurrence in the unperturbed year of patient enrollment.
190 Second, there might be a threshold for the number of prevented events for an individual (or at the population scale) which
191 becomes relevant from a clinical or health economic standpoint. One may assume that e.g., one prevented URTI could be
192 regarded as relevant, but we could not identify any guidance on that topic. Here again, we found that trials under medium and
193 strong NPI scenarios do not fulfil our criterion of $AB > 1$ prevented RTI that could be indicative of a true clinical benefit.

194 The Effect Model methodology^{42,43}, which may be obtained from meta-analyzing existing clinical data or simulation, is
195 a tool to rationalize control vs. treated group event rates directly. Consequently both clinically meaningful and statistically
196 demonstrable efficacy can be indicated in one analysis. In the optimal setting, the metrics used to demonstrate the efficacy with
197 a statistical test go hand in hand with the size of the effect relevant for the benefit-risk assessment. This predictivity, however,
198 seems to be weak under pandemic conditions given the ascertained dichotomy of NPI on AB and ERR. Under the medium NPI
199 scenario, a substantial portion of trials with positive primary endpoint evaluation could be challenged for clinical relevance of
200 the results and, in fact, clinical benefit-related metrics seem to be the most restrictive criteria when used to assess trial feasibility
201 *a priori*. We concluded from this analysis that clinical studies need to anticipate potentially weak representativity of traditional
202 or practical endpoints for benefit-risk assessment and that either more relevant endpoints need to be chosen or feasibility studies
203 (including computational studies such as trial simulation) should be conducted for potential trial design adjustments.

204 Our simulation setup for this analysis (year 1: patient selection, year 2: treatment and follow-up period) reflects RTI
205 prophylaxis trials whose conduction takes place during the current pandemic. Therefore, we concluded that the benefit-
206 risk assessment of these trials should account for the currently reduced disease burden, and that supporting data (such as
207 observational studies and models) should be used to demonstrate that a low number of prevented episodes under pandemic
208 conditions does not necessarily mean that under normal conditions equally few episodes will be prevented.

209 Recruitment issues are probably the earliest and a very important indicator for difficulties to conduct clinical trials in the
210 current COVID-19 pandemic era. For respiratory disease trials, such issues may be notably due to large sample size estimates
211 and fewer eligible patients. NPI introduced during the follow-up period, but not during the observation period, merely scales the
212 number of prevented events in year 2 for an already recruited population (NPI not present in year 1). Therefore, the included
213 at-risk population (nor their immunological characteristics) are not altered in such scenarios as compared to the non-perturbed
214 one. As the ERR used for statistical efficacy testing is a metric relative to the rate of events in the control group, it is robust
215 towards fluctuations in the overall disease burden by design. Therefore, our analysis of estimated sample size for NPI-corrected
216 efficacy (based on event rate ratios) did not show considerably increased recruitment needs (Figure 3e). Assuming that (e.g. for
217 a trial with a fixed budget) an enrollment of 200 eligible patients is feasible, demonstration of efficacy in all but the strongest
218 (25% reduction) NPI scenario, being introduced at the beginning of year 2, remains possible with the sample size planned under
219 no-NPI scenario. We thus conclude that estimated large sample sizes and the associated issues for recruiting high numbers of
220 patients are currently not a major difficulty for trials which have started and completed enrolment before 2020.

221 By considering NPI during the observational period in year 1 of a 2-year trial, we can highlight the collateral effects of
222 COVID-19 during patient recruitment which are caused by a reduction of the size of the pool of eligible patients. At-risk
223 populations for a given age-range are included based on their history during a reference period (e.g., number of RTI episodes
224 during the preceding 12 months) where risk for RTI is then defined as the average number of infections per average number of
225 viral exposures (assumed to be a constant in that time period). In practice, in trials targeting patients aged 1 to 6 years with
226 recurring RTI, patients with at least four to six RTI are included while the general populations suffer from e.g., only three
227 episodes on average during the same time. This way of enriching the population with individuals at elevated risk, however,
228 depends of the assumption that the virus exposure is a constant and that consequently the number of RTIs in the general
229 population is also a constant. A reduction of the overall disease burden (e.g. by NPI) however, decreases the number of
230 exposures and average number of RTIs in general. Consequently, in our simulations, small reductions of viral transmission
231 already led to a reduced number of virtual patients who comply with any fixed definition of recurrent RTIs. We could translate
232 this effect into a metric for recruitment difficulties, by considering the eligible fraction of the virtual population compared to the
233 general virtual population and a defined fixed screening rate (Figure 3f). Under mild NPIs, recruitment time already increased
234 by approximately 50%, which questions the feasibility to recruit enough patients in time especially for trials with a total
235 planned duration of 6 to 12 months. Estimated recruitment times of 3-4 years for a medium NPI scenario significantly exceed
236 the 12 months follow-up time of most trials and can thus be considered infeasible. As these analyses do not reflect any further
237 behavioral changes and psychological effects (e.g. fear to contract COVID-19) contributing to barriers to participate in clinical
238 trials, the presented analysis represents an optimistic scenario. Further, we did not yet account for year-to-year fluctuations in
239 the transmission of respiratory viruses that could add to the perturbation of NPIs (or cancel it out). Nevertheless, as it is the only
240 scenario where recruitment time does not exceed a 12-months follow-up, the mild NPI scenario is probably the only reasonable

241 condition compatible with recruiting enough patients for RTI prophylaxis trials under real-world conditions. Considering
242 that during the first UK lockdown, transmission reduction by 17.5% best reproduces the disease burden data, 5% reduction
243 as in the mild NPI scenario is a plausible assumption for a long-term effect on viral transmission (e.g., masks, a threshold
244 number of people in events, hand sanitizers in public places). To conclude, the selection of patients with recurrent RTI based
245 on pre-pandemic historical data would only include a very small fraction of patients, thus, we suggest considering eligibility
246 criteria tailored to the current incidence of RTI at a given time to avoid misalignment of targeted and included population. But
247 then, selecting the right at-risk population could become more challenging in turn.

248 Overall, we present here a mechanistic *in silico* clinical trial approach in RTI prophylaxis which can incorporate available
249 disease burden data to output efficacy metrics relevant for assessing clinical benefits and estimating sample sizes in perturbed
250 scenarios (or evaluating impact on the post-hoc power of a trial for a given sample size) as well as recruitment times. Mechanistic
251 description of the transmission of respiratory viruses can thereby translate lockdown and social distancing measures into a
252 decreased rate of RTI events in patients, and into a shift of the risk-dependent efficacy for OM-85 treatment in clinical trial
253 simulations. We highlighted that statistical significance of efficacy may be less predictive of the clinical benefit because there
254 are fewer events to prevent (due to collateral impact of COVID-19 containment), and consequently benefit-risk assessment
255 based on current RTI-prophylaxis trials might be difficult to establish. Recruitment of patients can be impeded as long as
256 intermittent lockdown or perturbations of seasonal virus transmission persist - in particular when trialists rely on pre-pandemic
257 historical data for trial design. Several open questions remain: What are the additional adjustments required for trial design to
258 account for the effect of the pandemic? How does the altered and shifted seasonality of respiratory viruses affect follow-up
259 duration? Is there a potential benefit of using inclusion criteria adapted to pandemic times (such as incidence matching) and do
260 those adaptations risk to confound efficacy? What happens if the forecast of the disease burden turns out to be wrong?

261 The limitations of traditional clinical trial design methodology and the proof of concept established in this Modeling &
262 Simulation study advocates for the use of mechanistic computational models to address these questions in detail and to support
263 go/no-go decisions in clinical development for a wide range of RTI prophylaxis-oriented treatments. Furthermore, when trials
264 are deemed infeasible, the models could harness RTI disease burden monitoring (and prediction of COVID-19 and its associated
265 containment measures) to indicate the time point when delayed or stopped trials can be restarted.

266 **Methods**

267 **Modeling approach**

268 The *in silico* clinical trials in this work are simulations performed with system models using ordinary differential equations
269 (ODEs) embedded in a virtual population approach where parameters are described by statistical distributions rather than scalar
270 values, in order to represent different sources of variability. Each virtual patient corresponds to a vector of parameter values,
271 drawn from the corresponding statistical distribution. Similar to a real clinical trial protocol, an *in silico* study protocol defines
272 the use of the model, virtual population, simulation scenarios and statistical analyses to answer a question of interest.

273 **Multiscale RTI disease and treatment model**

274 The core element of the computational approach is the coupling of a within-host mechanistic disease model, representing the
275 viral and immune dynamics, with a between-host disease burden model, representing the viral dynamics at the population-scale
276 with a Susceptible, Infectious, Recovered, Susceptible (SIRS) framework, to obtain a multiscale RTI and immunomodulation
277 model (Figure 1). The immunological and the SIRS models are both ODEs-based deterministic models (equations and
278 parameters provided in the Supplementary Methods).

279 *Immunological within-host viral infection model*

280 The immunological model, implementing lytic versus nonlytic immune mechanisms during viral infection, was designed based
281 on Wodarz *et al.* (2002)⁴⁴ to simulate the within-host dynamics in response to respiratory virus exposure (co-infections are
282 not accounted) (bottom part of Figure 1, Supplementary Methods, Supplementary Figure S2, Supplementary Table S1). To
283 translate individual occurrences of RTI events for a given patient over time into the distributions of RTI rates in the population,
284 inter- and intra-individual variability need to be taken into account. For this, stochastic processes determine time points of viral
285 exposure and current state of antiviral defenses. A patient-specific state of antiviral defenses (immuno-competence) is therefore
286 distributed in the population and a layer of random fluctuations is added around each individual value. Both distributions
287 were calibrated so that the RTI distribution in the virtual population represents a reference RTI prevalence distribution data set
288 (obtained from a reference birth cohort⁴¹). Describing age as a covariate for this distribution required inclusion of a maturation
289 term into the immune effector functions to reproduce the higher risk for RTI in young children due the still developing immune
290 system (Supplementary Methods, Supplementary Figure S3).

291 *Between-host viral infection and disease burden model*

292 RTI disease burden was simulated using a SIRS model (described in Supplementary Methods: Between-host SIRS model)

293 inspired by general literature on such models⁴⁵. This SIRS model accounts for the seasonality of infection in an averaged
294 manner in a given population; it is based on time-dependent transmission rates of selected viruses reproducing the seasonality
295 of upper and lower RTIs attributed to RSV, RV and Influenza viruses (Supplementary Figure S4, Supplementary Table S2). We
296 first ran the epidemiological model alone with NPI-adjusted transmission rate (reduction of mean transmission rates b_0 by 0%,
297 5%, 15%, 25%) and compared it with data digitized from the communicable and respiratory disease reports from 2019 to 2020
298 published in the UK by the Royal College of General Practitioners (RCGP)³⁴. The outcome of the SIRS model was then used
299 to provide the data for the time-dependent instantaneous prevalence of RTI for the rest of the model.

300 *Treatment model*

301 To describe the immuno-modulating effect of OM-85 in RTI prophylaxis, a physiologically based pharmacokinetics and
302 pharmacodynamics (PBPK/PD) model is linked to the immunological model through ingress in the respiratory tract of
303 reprogrammed type-1 innate memory like cells⁴⁶, regulatory T-cells⁴⁷⁻⁴⁹, and polyclonal IgA producing plasma cells^{50,51}
304 originating from the intestinal Peyer's patches (Supplementary Figure S5) according to the current understanding of OM-85's
305 mechanism of action. Implementation of administration, distribution, metabolism and excretion follows common published
306 approaches (Supplementary Methods: PBPK/PD model of OM-85 effect). In absence of OM-85 PK data, the unknown PBPK
307 drug-specific parameters were calibrated using rodent PK data of a similar product (OM-89)^{52,53} and were allometrically scaled
308 to human physiology (Supplementary Figure S6, Supplementary Table S3). Unknown PD-relevant parameters were calibrated
309 and checked using two sets of human PD response data under different treatment regimens (Supplementary Figure S7-8,
310 Supplementary Table S4). Calibration of remaining parameters that quantify the size of the efficacy of OM-85 was performed
311 based on the meta-analysis of Yin *et al.*⁵⁴ (Supplementary Methods: Calibration of OM-85 clinical efficacy, Supplementary
312 Figure S10-11).

313 *In silico* clinical trial simulations

314 We simulated placebo-controlled parallel two-arm trials of RTI prevention with OM-85 in pediatric subjects with 24 months
315 duration (observational period of 1 year followed by a follow-up period of 1 year composed of 3 consecutive months of
316 treatment followed by 9 without any treatment). A virtual population of more than 100,000 virtual patients was generated. The
317 entire virtual population was screened during the observational period in the first year of the trial. After the first year, eligibility
318 criteria were evaluated and randomization was performed. In line with the range of annual RTI episodes typically defining
319 recurrent RTIs (3-6), children that experienced at least 5 RTIs were included into the follow-up period. Included virtual subjects
320 were randomly allocated with equal weight to the interventional and control arms. During the first 3 months of the follow-up
321 period, OM-85 was administered every day during the first 10 consecutive days of each month, in line with the current approved
322 dosing regimen of OM-85 in the prevention of RTIs. The primary outcome was the number of RTIs during one-year follow-up,
323 which was assessed at the end of trial. 600 *in silico* clinical trials were simulated for each of the four different NPI scenarios
324 (reduction of the transmission rate by 0, 5%, 15%, 25%) by randomly sampling 50 subjects per arm from the screened virtual
325 population (studies meta analyzed by Yin *et al.*⁵⁴ have enrolled in average 45.4 patients per arm).

326 Mechanistic uncertainty analysis

327 To assess the effect of main drivers of uncertainty represented in the model (i.e., treatment efficacy related parameters) we
328 simulated different mechanistic scenarios in parallel throughout the modeling procedure and analyses. We used 12 different
329 conditions (testing different immunogenic hypotheses on the effect of OM-85, (Supplementary Methods: Mechanistic uncertainty
330 management) for each of the 4 NPI scenarios. We pooled the results, as these variations of OM-85 immunogenicity may indeed
331 contribute to the overall outcome (e.g. efficacy) variability.

332 Efficacy analysis

333 The Effect Model approach^{42,55} is a tool which relates the rates (or risks) of events without treatment (R_c) and with (R_t), as
334 supported by empirical evidence, simulations and theoretical considerations⁵⁶⁻⁵⁹. While simulations can be conducted for the
335 same patient in different arms in *in silico* trials and yield paired observations, the Effect Model can also be reconciled with
336 meta-analyses^{56,60}. Here we have used a similar approach which compares RTI rates in a series of individual *in silico* clinical
337 trials, thus not reporting individual, but risk-stratified group metrics. As efficacy metrics, we consider absolute benefit (AB) and
338 the event rate ratio (ERR). Average ERR and AB were assessed at one-year follow up. AB determined from a single *in silico*
339 trial is the arithmetic difference between mean RTI rate in the control group (R_c) and in the treatment group (R_t). ERR refers to
340 the ratio R_t/R_c . Distribution of the ERR and AB per scenario contain pooled results for different mechanistic conditions and
341 visualized as maximum interquartile range (defined as the difference between maximum 75th percentile and minimum 25th
342 percentile across mechanistic conditions). AB and ERR were analyzed with a paired t-test/ANOVA with α level set at .05.

Sample size and recruitment estimation

Sample size calculations for primary endpoint analyses of RTI prophylaxis trials require an adapted statistical method for overdispersed count data. We performed generalized linear regression analysis with negative binomial distributions (mean and dispersion parameter, `glm` function of the R package MASS) for the subsequent use of these parameters in the sample size calculation method proposed by Zhu *et al.* (2013)⁶¹. Calculations employed the `power.nb.test` function of the MKmisc package given the ratio of rates in both trial arms, average dispersion parameter, an α of 0.025 and correction for average study duration (e.g. due to dropout $\kappa=0.75$). Based on sample size calculations and the fraction of the entire Virtual Population eligible for inclusion, time to recruitment was calculated, assuming that in a typical study in respiratory diseases a screening rate of 1000 patients per year can be achieved per center.

References

1. Tušl, M., Brauchli, R., Kerksieck, P. & Bauer, G. F. Impact of the COVID-19 crisis on work and private life, mental well-being and self-rated health in german and swiss employees: a cross-sectional online survey. *BMC Public Heal.* **21**, DOI: [10.1186/s12889-021-10788-8](https://doi.org/10.1186/s12889-021-10788-8) (2021).
2. Ayati, N., Saiyarsarai, P. & Nikfar, S. Short and long term impacts of COVID-19 on the pharmaceutical sector. *DARU J. Pharm. Sci.* **28**, 799–805, DOI: [10.1007/s40199-020-00358-5](https://doi.org/10.1007/s40199-020-00358-5) (2020).
3. Taylor, P. C. *et al.* Neutralizing monoclonal antibodies for treatment of COVID-19. *Nat. Rev. Immunol.* **21**, 382–393, DOI: [10.1038/s41577-021-00542-x](https://doi.org/10.1038/s41577-021-00542-x) (2021).
4. Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B. & Prado, E. O. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. *npj Vaccines* **6**, DOI: [10.1038/s41541-021-00292-w](https://doi.org/10.1038/s41541-021-00292-w) (2021).
5. Heimfarth, L., Serafini, M. R., Martins-Filho, P. R., de Souza Siqueira Quintans, J. & Quintans-Júnior, L. J. Drug repurposing and cytokine management in response to COVID-19: A review. *Int. Immunopharmacol.* **88**, 106947, DOI: [10.1016/j.intimp.2020.106947](https://doi.org/10.1016/j.intimp.2020.106947) (2020).
6. Gysi, D. M. *et al.* Network medicine framework for identifying drug-repurposing opportunities for COVID-19. *Proc. Natl. Acad. Sci.* **118**, e2025581118, DOI: [10.1073/pnas.2025581118](https://doi.org/10.1073/pnas.2025581118) (2021).
7. Sathian, B. *et al.* Impact of COVID-19 on clinical trials and clinical research: A systematic review. *Nepal J. Epidemiol.* **10**, 878–887, DOI: [10.3126/nje.v10i3.31622](https://doi.org/10.3126/nje.v10i3.31622) (2020).
8. Unger, J. M. & Xiao, H. The COVID-19 pandemic and new clinical trial activations. *Trials* **22**, DOI: [10.1186/s13063-021-05219-3](https://doi.org/10.1186/s13063-021-05219-3) (2021).
9. Upadhaya, S., Yu, J. X., Hodge, J. & Campbell, J. COVID-19 impact on oncology clinical trials: a 1-year analysis. *Nat. Rev. Drug Discov.* **20**, 415–415, DOI: [10.1038/d41573-021-00086-8](https://doi.org/10.1038/d41573-021-00086-8) (2021).
10. Upadhaya, S. *et al.* Impact of COVID-19 on oncology clinical trials. *Nat. Rev. Drug Discov.* **19**, 376–377, DOI: [10.1038/d41573-020-00093-1](https://doi.org/10.1038/d41573-020-00093-1) (2020).
11. Ledford, H. The COVID pandemic’s lingering impact on clinical trials. *Nature* DOI: [10.1038/d41586-021-01569-9](https://doi.org/10.1038/d41586-021-01569-9) (2021).
12. Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science* **368**, 860–868, DOI: [10.1126/science.abb5793](https://doi.org/10.1126/science.abb5793) (2020).
13. Ruopp, M., Chiswell, K., Thaden, J. T., Merchant, K. & Tsalik, E. L. Respiratory tract infection clinical trials from 2007 to 2012. a systematic review of ClinicalTrials.gov. *Annals Am. Thorac. Soc.* **12**, 1852–1863, DOI: [10.1513/annalsats.201505-291oc](https://doi.org/10.1513/annalsats.201505-291oc) (2015).
14. Bodini, R. *et al.* Epidemiology of clinical trials of medicines in respiratory diseases in europe and italy. *Respir. Medicine* **125**, 8–11, DOI: [10.1016/j.rmed.2017.02.009](https://doi.org/10.1016/j.rmed.2017.02.009) (2017).
15. Alqahtani, J. S. *et al.* Reduction in copd exacerbations during covid-19: a systematic review and meta-analysis. *medRxiv* DOI: [10.1101/2021.05.17.21257335](https://doi.org/10.1101/2021.05.17.21257335) (2021).
16. Dilworth, T. J. & Brummitt, C. F. Reduction in ambulatory visits for acute, uncomplicated bronchitis: an unintended but welcome result of the coronavirus disease 2019 (COVID-19) pandemic. *Infect. Control. & Hosp. Epidemiol.* 1–2, DOI: [10.1017/ice.2020.1233](https://doi.org/10.1017/ice.2020.1233) (2020).
17. Jones, N. How COVID-19 is changing the cold and flu season. *Nature* **588**, 388–390, DOI: [10.1038/d41586-020-03519-3](https://doi.org/10.1038/d41586-020-03519-3) (2020).
18. Varela, F. H. *et al.* Absence of detection of RSV and influenza during the COVID-19 pandemic in a brazilian cohort: Likely role of lower transmission in the community. *J. Glob. Heal.* **11**, DOI: [10.7189/jogh.11.05007](https://doi.org/10.7189/jogh.11.05007) (2021).

- 392 **19.** Brusselen, D. V. *et al.* Bronchiolitis in COVID-19 times: a nearly absent disease? *Eur. J. Pediatr.* **180**, 1969–1973, DOI:
393 [10.1007/s00431-021-03968-6](https://doi.org/10.1007/s00431-021-03968-6) (2021).
- 394 **20.** Iacobucci, G. Covid lockdown: England sees fewer cases of colds, flu, and bronchitis. *BMJ* **m3182**, DOI: [10.1136/bmj.](https://doi.org/10.1136/bmj.m3182)
395 [m3182](https://doi.org/10.1136/bmj.m3182) (2020).
- 396 **21.** Friedrich, F. *et al.* Early impact of social distancing in response to coronavirus disease 2019 on hospitalizations for acute
397 bronchiolitis in infants in brazil. *Clin. Infect. Dis.* **72**, 2071–2075, DOI: [10.1093/cid/ciaa1458](https://doi.org/10.1093/cid/ciaa1458) (2020).
- 398 **22.** Alsallakh, M. A. *et al.* Impact of COVID-19 lockdown on the incidence and mortality of acute exacerbations of chronic
399 obstructive pulmonary disease: national interrupted time series analyses for scotland and wales. *BMC Medicine* **19**, DOI:
400 [10.1186/s12916-021-02000-w](https://doi.org/10.1186/s12916-021-02000-w) (2021).
- 401 **23.** Faria, N., Costa, M. I., Gomes, J. & Sucena, M. Reduction of severe exacerbations of COPD during COVID-19
402 pandemic in portugal: A protective role of face masks? *COPD: J. Chronic Obstr. Pulm. Dis.* **18**, 226–230, DOI:
403 [10.1080/15412555.2021.1904387](https://doi.org/10.1080/15412555.2021.1904387) (2021).
- 404 **24.** Salciccioli, J. D. *et al.* Effect of COVID-19 on asthma exacerbation. *The J. Allergy Clin. Immunol. In Pract.* **9**, 2896–
405 2899.e1, DOI: [10.1016/j.jaip.2021.04.038](https://doi.org/10.1016/j.jaip.2021.04.038) (2021).
- 406 **25.** Agha, R. & Avner, J. R. Delayed seasonal rsv surge observed during the covid-19 pandemic. *Pediatrics* **148**, DOI:
407 [10.1542/peds.2021-052089](https://doi.org/10.1542/peds.2021-052089) (2021).
- 408 **26.** Hussain, F., Kotecha, S. & Edwards, M. O. Rsv bronchiolitis season 2021 has arrived, so be prepared! *Arch. Dis. Child.*
409 DOI: [10.1136/archdischild-2021-322835](https://doi.org/10.1136/archdischild-2021-322835) (2021).
- 410 **27.** Holford, N. H. G., Kimko, H. C., Monteleone, J. P. R. & Peck, C. C. Simulation of clinical trials. *Annu. Rev. Pharmacol.*
411 *Toxicol.* **40**, 209–234, DOI: [10.1146/annurev.pharmtox.40.1.209](https://doi.org/10.1146/annurev.pharmtox.40.1.209) (2000).
- 412 **28.** Pappalardo, F., Russo, G., Tshinanu, F. M. & Viceconti, M. In silico clinical trials: concepts and early adoptions. *Briefings*
413 *Bioinforma.* **20**, 1699–1708, DOI: [10.1093/bib/bby043](https://doi.org/10.1093/bib/bby043) (2018).
- 414 **29.** Bajard, A. *et al.* An in silico approach helped to identify the best experimental design, population, and outcome for future
415 randomized clinical trials. **69**, 125–136, DOI: [10.1016/j.jclinepi.2015.06.024](https://doi.org/10.1016/j.jclinepi.2015.06.024) (2016).
- 416 **30.** Wang, Y. *et al.* Model-informed drug development: Current US regulatory practice and future considerations. *Clin.*
417 *Pharmacol. & Ther.* **105**, 899–911, DOI: [10.1002/cpt.1363](https://doi.org/10.1002/cpt.1363) (2019).
- 418 **31.** Li, L. *et al.* *CPT: pharmacometrics & systems pharmacology* **8**, 59, DOI: [10.1002/psp4.12368](https://doi.org/10.1002/psp4.12368) (2019).
- 419 **32.** Adam, D. Special report: The simulations driving the world’s response to COVID-19. *Nature* **580**, 316–318, DOI:
420 [10.1038/d41586-020-01003-6](https://doi.org/10.1038/d41586-020-01003-6) (2020).
- 421 **33.** Dodds, M. G., Krishna, R., Goncalves, A. & Rayner, C. R. Model-informed drug repurposing: Viral kinetic modelling to
422 prioritize rational drug combinations for COVID-19. *Br. J. Clin. Pharmacol.* **87**, 3439–3450, DOI: [10.1111/bcp.14486](https://doi.org/10.1111/bcp.14486)
423 (2020).
- 424 **34.** Royal College of General Practitioners (RCGP) Research & Surveillance Centre. RSC communicable and respiratory
425 disease report for england - week 31. Tech. Rep., University of Oxford, University of Surrey (2020).
- 426 **35.** Timeline of uk coronavirus lockdowns, march 2020 to march 2021. [https://www.instituteforgovernment.org.uk/sites/](https://www.instituteforgovernment.org.uk/sites/default/files/timeline-lockdown-web.pdf)
427 [default/files/timeline-lockdown-web.pdf](https://www.instituteforgovernment.org.uk/sites/default/files/timeline-lockdown-web.pdf). Accessed: 2021-07-06.
- 428 **36.** Tripepi, G., Jager, K., Dekker, F., Wanner, C. & Zoccali, C. Measures of effect: relative risks, odds ratios, risk difference,
429 and number needed to treat. *Kidney international* **72**, 789–791, DOI: [10.1038/sj.ki.5002432](https://doi.org/10.1038/sj.ki.5002432) (2007).
- 430 **37.** Boissel, J.-P., Cogny, F., Marko, N. & Boissel, F.-H. From clinical trial efficacy to real-life effectiveness: Why conventional
431 metrics do not work. **6**, 125–132, DOI: [10.1007/s40801-019-0159-z](https://doi.org/10.1007/s40801-019-0159-z) (2019).
- 432 **38.** Schaad, U. B. Prevention of paediatric respiratory tract infections: emphasis on the role of OM-85. **14**, 74–77, DOI:
433 [10.1183/09059180.05.00009506](https://doi.org/10.1183/09059180.05.00009506) (2005).
- 434 **39.** Young, L. J., Campbell, N. L. & Capuano, G. A. Analysis of overdispersed count data from single-factor experiments: A
435 comparative study. **4**, 258, DOI: [10.2307/1400385](https://doi.org/10.2307/1400385) (1999).
- 436 **40.** Aban, I. B., Cutter, G. R. & Mavinga, N. Inferences and power analysis concerning two negative binomial distributions
437 with an application to MRI lesion counts data. **53**, 820–833, DOI: [10.1016/j.csda.2008.07.034](https://doi.org/10.1016/j.csda.2008.07.034) (2009).
- 438 **41.** Carlsson, C. J. *et al.* Duration of wheezy episodes in early childhood is independent of the microbial trigger. *J. Allergy*
439 *Clin. Immunol.* **136**, 1208–1214.e5, DOI: [10.1016/j.jaci.2015.05.003](https://doi.org/10.1016/j.jaci.2015.05.003) (2015).

- 440 **42.** Boissel, J.-P. *et al.* Towards personalized medicine: exploring the consequences of the effect model-based approach. *Pers.*
441 *Medicine* **8**, 581–586, DOI: [10.2217/pme.11.54](https://doi.org/10.2217/pme.11.54) (2011).
- 442 **43.** Boissel, J.-P., Auffray, C., Noble, D., Hood, L. & Boissel, F.-H. Bridging systems medicine and patient needs. *CPT:*
443 *Pharmacometrics & Syst. Pharmacol.* **4**, 135–145, DOI: [10.1002/psp4.26](https://doi.org/10.1002/psp4.26) (2015).
- 444 **44.** Wodarz, D. The importance of lytic and nonlytic immune responses in viral infections. *Trends Immunol.* **23**, 194–200,
445 DOI: [10.1016/s1471-4906\(02\)02189-0](https://doi.org/10.1016/s1471-4906(02)02189-0) (2002).
- 446 **45.** Kermack, W. O. & McKendrick, A. G. A contribution to the mathematical theory of epidemics. **115**, 700–721, DOI:
447 [10.1098/rspa.1927.0118](https://doi.org/10.1098/rspa.1927.0118) (1927).
- 448 **46.** Wang, Peng, H. & Tian, Z. Innate lymphoid cell memory. *Cell. & Mol. Immunol.* **16**, 423–429, DOI: [10.1038/](https://doi.org/10.1038/s41423-019-0212-6)
449 [s41423-019-0212-6](https://doi.org/10.1038/s41423-019-0212-6) (2019).
- 450 **47.** Navarro, S. *et al.* The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory t cells to
451 the airways. **4**, 53–65, DOI: [10.1038/mi.2010.51](https://doi.org/10.1038/mi.2010.51) (2010).
- 452 **48.** Strickland, D. H. *et al.* Boosting airway t-regulatory cells by gastrointestinal stimulation as a strategy for asthma control.
453 **4**, 43–52, DOI: [10.1038/mi.2010.43](https://doi.org/10.1038/mi.2010.43) (2010).
- 454 **49.** Fu, R. *et al.* Broncho-vaxom attenuates allergic airway inflammation by restoring GSK3-related t regulatory cell
455 insufficiency. **9**, DOI: [10.1371/journal.pone.0092912](https://doi.org/10.1371/journal.pone.0092912) (2014).
- 456 **50.** Emmerich, B., Pachmann, K., Milatovic, D. & Emslander, H. Influence of OM-85 BV on Different Humoral and Cellular
457 Immune Defense Mechanisms of the Respiratory Tract. *Respiration* **59**, 19–23, DOI: [10.1159/000196126](https://doi.org/10.1159/000196126) (2009).
- 458 **51.** Lusuardi, M. *et al.* Local Airways Immune Modifications Induced by Oral Bacterial Extracts in Chronic Bronchitis. *Chest*
459 **103**, 1783–1791, DOI: [10.1378/chest.103.6.1783](https://doi.org/10.1378/chest.103.6.1783) (1993).
- 460 **52.** van Dijk, A., Bauer, J., Sedelmeier, E. A. & Bessler, W. G. Absorption, kinetics, antibody-bound and free serum
461 determination of a 14C-labeled Escherichia coli extract after single oral administration in rats. *Arzneimittelforschung* **47**,
462 329–334 (1997).
- 463 **53.** Burckhart, M. F., Mimouni, J. & Fontanges, R. Absorption kinetics of a 14c-labelled escherichia coli extract after oral
464 administration in mice. *Arzneimittel-Forschung* **47**, 325–328 (1997).
- 465 **54.** Yin, J., Xu, B., Zeng, X. & Shen, K. Broncho-vaxom in pediatric recurrent respiratory tract infections: A systematic review
466 and meta-analysis. *Int. immunopharmacology* **54**, 198–209, DOI: [10.1016/j.intimp.2017.10.032](https://doi.org/10.1016/j.intimp.2017.10.032) (2018).
- 467 **55.** Boissel, J.-P., Kahoul, R., Marin, D. & Boissel, F.-H. Effect model law: An approach for the implementation of personalized
468 medicine. *JPM* **3**, 177–190, DOI: [10.3390/jpm3030177](https://doi.org/10.3390/jpm3030177) (2013).
- 469 **56.** Boissel, J.-P., Collet, J.-P., Lievre, M. & Girard, P. An effect model for the assessment of drug benefit: example of
470 antiarrhythmic drugs in postmyocardial infarction patients. *J. cardiovascular pharmacology* **22**, 356–363 (1993).
- 471 **57.** Boissel, J.-P. Individualizing aspirin therapy for prevention of cardiovascular events. *JAMA* **280**, 1949, DOI: [10.1001/jama.](https://doi.org/10.1001/jama.280.22.1949)
472 [280.22.1949](https://doi.org/10.1001/jama.280.22.1949) (1998).
- 473 **58.** Glasziou, P. P. & Irwig, L. M. An evidence based approach to individualising treatment. *BMJ* **311**, 1356–1359, DOI:
474 [10.1136/bmj.311.7016.1356](https://doi.org/10.1136/bmj.311.7016.1356) (1995).
- 475 **59.** Wang, H., Boissel, J.-P. & Nony, P. Revisiting the relationship between baseline risk and risk under treatment. *Emerg.*
476 *Themes Epidemiol.* **6**, DOI: [10.1186/1742-7622-6-1](https://doi.org/10.1186/1742-7622-6-1) (2009).
- 477 **60.** Boissel, J.-P. *et al.* New insights on the relation between untreated and treated outcomes for a given therapy effect model is
478 not necessarily linear. *J. clinical epidemiology* **61**, 301–307 (2008).
- 479 **61.** Zhu, H. & Lakkis, H. Sample size calculation for comparing two negative binomial rates. *Stat. Med.* **33**, 376–387, DOI:
480 [10.1002/sim.5947](https://doi.org/10.1002/sim.5947) (2013).

481 Acknowledgements

482 We acknowledge feedback by Jim Bosley and Shiny Martis B. on the manuscript draft.

483 Author contributions statement

484 A.K., S.A., L.L., C.P and A.C. supervised the study. S.A, C.C, I.F, N.G., S.G.N., D.S., developed the model, performed
485 simulations and analyzed the results. S.A. and A.K wrote the manuscript. All authors contributed to the discussion of the
486 results and reviewed the manuscript.

487 **Additional information**

488 AK, SA, CC, IF, NG, SGN, DS, RK, BI, JPB are employees of Novartis. AC, LL, CP are employees of OM Pharma.
489 Novartis and OM Pharma funded the study.

490 The datasets generated during and/or analysed during the current study are available from the corresponding author on
491 reasonable request.




Figure 1. Multi-scale *in silico* approach to incorporate within-host and between-host respiratory tract infection (RTI) model as well as a treatment model with bacterial lysate OM-85. The model is used to assess feasibility of clinical trials in prophylaxis of RTIs during COVID-19 pandemic. The transmission of the major respiratory pathogens RSV, rhinovirus and influenza type A and B viruses is given by a seasonal SIRS model (between-host model). This model is interfaced to a within-host immunology model via a time-dependent instantaneous prevalence of infection triggering or not viral exposure at randomly chosen time points. Individual patients are identified by their age and an immuno-competence meta-parameter impacting the immune response from which infections are included or omitted from the cumulative number of infections depending on viremia. To prevent RTIs, virtual patients are treated with the bacterial lysate OM-85 which acts through a pro-type I immunomodulation mechanism of action and which is described by a physiologically based pharmacokinetics and pharmacodynamics approach (treatment model) with downstream effects in the immunological model. The impact of COVID-19 associated non-pharmaceutical interventions (NPIs) are simulated by scaling of the transmission term in the between-host part of the model. Figure created with BioRender.com.




Figure 2. Between-host model based on SIRS framework allows to reproduce RTI incidence during non-pharmaceutical interventions (NPIs) to mitigate COVID-19 pandemic. a) Schematic of implemented SIRS model where NPI can be modelled by a decrease of the transmission rate. **b)** Comparison of model predictions (dashed lines) and data (solid lines) from RCGP³⁴ for RTI weekly incidence (per 100,000 all ages) for the 5 years average (green) and 2020 (orange). Lockdown was started on the 23th of March 2020 in the UK. This date was used to implement the lockdown in the simulations with a decrease of 17.5% of the transmission rate.




Figure 3. Results of *in silico* clinical trials in prophylaxis of respiratory tract infections (RTIs) with four scenarios of non-pharmaceutical interventions (NPIs) against COVID-19 pandemic with increasing strength (absent, mild, medium and strong) modelled by a decrease of the transmission rate parameter (no reduction, -5%, -15% and -25%, respectively). For all scenarios, the simulations are run for 2 years. Year 1 is the selection year during which patients are screened and possibly included in an *in silico* trial. There is no NPI during year 1. The NPIs are started at the beginning of year 2 as well as the treatment (10 daily administrations of 3.5 mg of OM-85 from the beginning of the month for 3 consecutive months). RTIs are counted for the complete duration of year 2. **a)** Weekly incidence of RTIs per 100,000 is plotted for two years of simulations for the four NPI scenarios. NPI is started at the beginning of year 2. **b)** Distribution (maximum IQR) of absolute benefit is plotted for the four NPI scenarios. Absolute benefit can be interpreted as the number of prevented RTIs in year 2 when comparing the treated and the control group. Maximum IQR is defined as the difference between maximum 75th percentile and minimum 25th percentile across mechanistic conditions. **c)** Distribution (maximum IQR) of event RTI rate ratio (ERR, treated over control group) is plotted for the four NPI scenarios. **d)** Effect Model plot for the four NPI scenarios. Each *in silico* clinical trial is plotted (cross) with the number of RTIs in the control group as x coordinate and the number of RTIs in the treated group as y coordinate. The region of clinically relevant efficacy is indicated in orange. It is defined by at least 1 prevented RTI in absolute benefit (dashed-dotted line), at least 20% reduction in number of RTIs (solid line) and least 3 RTIs in the control group. By that criteria, only trials with absent or mild NPI scenario are deemed feasible. **e)** Distribution (maximum IQR) of sample sizes per arm required to show efficacy of OM-85 treatment in reducing number of RTIs for the four NPI scenarios. **f)** Distribution (maximum IQR) of estimated patient screening times under the four NPI scenarios by assuming an hypothetical screening rate of 1,000 patients per year and by taking year 2 as the selection year (without treatment).